SERNOVA AND SERAXIS CLOSE US$11.2 MILLION FINANCING TO FUND MERGER TO BECOME BETANOVA BIOTHERAPEUTICS AND ADVANCE TYPE 1 DIABETES CELL THERAPY INTO NEAR TERM PHASE 1/2 CLINICAL TRIAL

Reuters · 3d ago

Please log in to view news